| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Izeltabart tapatansine | IMGC-936 | Phase 2 Clinical | Immunogen Inc | Solid tumours | Details |
| DB-1317 | DB-1317 | Phase 1 Clinical | Duality Biologics (Suzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| MGC-028 | MGC028; MGC-028 | Phase 1 Clinical | Macrogenics Inc | Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |